{"database": "openregs", "table": "documents", "rows": [["CDC-2020-0046-0141", "CDC", "CDC-2020-0046", "Request for Public Comment on NIOSH Initial Recommendations To Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings", "Notice", null, "2024-01-16T05:00:00Z", 2024, 1, "2024-01-16T05:00:00Z", "2024-02-16T04:59:59Z", "2024-02-16T02:00:32Z", "2024-00693", 0, 0, "090000648639cec4"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["CDC-2020-0046-0141"], "units": {}, "query_ms": 1.3392099644988775, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}